Allergan releases Viberzi data & more — 7 GI company key notes

Here are seven updates on GI companies from the past week:

Allergan released data from two phase III studies evaluating the efficacy and safety of Viberzi.

Effector Therapeutics partnered with Pfizer and Merck to evaluate two immuno-oncology agents in patients with microsatellite stable colorectal cancer.

Sucampo Pharmaceuticals is focusing its efforts on growing its Amitiza digestive disease line.

Pentax Medical and Shanghai Aohua Photoelectricity Endoscope Co. created Pentax-Aohua Medical Technologies, Co., a joint venture company aimed at creating new flexible endoscope products.

Promega Corp. will seek FDA and European regulatory approval for its Microsatellite Instability assay.

Valeant Pharmaceuticals used $811 million of the $819.9 million it received for selling Dendreon Pharmaceuticals to pay down some of the company's senior secured loans.

Immuron Limited released preliminary results from its IMM-124E phase II study of nonalcoholic steatohepatitis patients.

More articles on gastroenterology:
GI leader to know: Dr. Faraz Bishehsari of University Gastroenterologists
Immuron's IMM-124E as effective as placebo for nonalcoholic steatohepatitis treatment — 4 study insights
Staying relevant — Dr. Larry Kosinski on the future of GI in ASCs

© Copyright ASC COMMUNICATIONS 2020. Interested in LINKING to or REPRINTING this content? View our policies by clicking here.


Featured Webinars

Featured Whitepapers